Therefore, pairing the envelope protein with the spike protein in COVID‐19 vaccines may not only induce adaptive T cell responses (or perhaps anti‐envelope protein antibodies that could block its binding with TLR4) but also act as an adjuvant. This evidence concerns the gene TLR4 and COVID-19.